IPO Plus

NSE · LOTUSEYE · Healthcare

Lotus Eye Hospital & Institute Ltd.

LT-ASM · ASM 1
119.51
market cap
P/E
194.17
EPS
₹-0.15
Book value
₹28.91
ROE
ROCE
2.99%
Debt / equity

Revenue & net profit by period

Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.

012.7225.4338.1550.86Mar 18Mar 19Mar 20Mar 21Mar 22Mar 23Mar 24Mar 25
Revenue (₹ Cr) Net profit (₹ Cr)

Latest period: revenue ₹51 Cr with net profit ₹1 Cr — a 1.45% net margin, versus 5.89% the period before.

Shareholding

As of 2026-06-30

40.14%
promoter holding
  • Promoter40.14%
  • Public59.85%
  • DII0.02%

9,627 shareholders on record

Promoter holding trend

Each disclosed period, oldest to newest

40.03%40.14%Sep 24Jun 26

52-week position

Where the current price sits in its yearly band

70.84120147

The band spans 2.08× from low to high.

Risk flags

Derived from disclosed data

  • Under exchange surveillance — LT-ASM · ASM 1. Trading may carry price bands, periodic call auction or higher margins.

Peer comparison

Medical Care Facilities · ranked #1 of 3 by market cap

P/E
194.17vs peer med
P/B
4.1vs peer med
ROE %
vs peer med
Margin %
vs peer med
CompanyMkt capP/EP/BROEMargin
Lotus Eye Hospital & Institute Ltd.(this company)194.174.13

AI analysis

AI-generated · google/gemini-2.5-flash

Lotus Eye Hospital & Institute Ltd. is listed with a market capitalization of Rs 253 Cr. The company reported revenue of Rs 50.86 Cr and an EPS of Rs 0.04. The debt-to-equity ratio stands at 0.04.

Positives

  • +The company's debt-to-equity ratio is low at 0.04.
  • +Return on equity (ROE) is 13.4% as of the latest annual data.

Negatives

  • Promoter pledging is high, with 87.15% of promoter shares pledged as of June 30, 2026.
  • The company recorded a net loss of Rs -0.32 Cr in the quarter ending March 2026.
  • The company is under LT-ASM surveillance, indicating regulatory attention.
  • The price-to-earnings (P/E) ratio is high at 194.17.
  • Return on Capital Employed (ROCE) is low at 1.0589%.

Financial performance

For the financial year ending March 2025, revenue was Rs 50.86 Cr, with a net profit of Rs 0.7393 Cr. This follows a revenue of Rs 49.5126 Cr and a net profit of Rs 2.9145 Cr in March 2024. Quarterly revenue for March 2026 was Rs 13.61 Cr, resulting in a net loss of Rs -0.32 Cr.

Profitability & returns

The company recorded a profit margin of 14.9%. Return on equity (ROE) was 13.4%, and return on capital employed (ROCE) was 1.0589%. The earnings per share (EPS) for the latest available annual period was Rs 0.04.

Balance sheet

Lotus Eye Hospital & Institute Ltd. has a low debt-to-equity ratio of 0.04. The book value per share is Rs 28.92. There are no dividend payouts reported, with the dividend yield at 0%.

Ownership & pledges

As of June 30, 2026, promoter holding was 40.1373%, with public shareholding at 59.8471%. DIIs held 0.0156% of shares, with no FII holding. A significant portion of promoter shares, 87.15%, is pledged. The number of shareholders was 9627.

Regulatory & surveillance

The company is currently under LT-ASM surveillance, specifically ASM Stage 1. This includes measures such as LT-ASM.

Data as of — price: 2026-07-29 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.

How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.

Back to Lotus Eye Hospital & Institute Ltd.share price & fundamentals

Telegram App